EMEA-002051-PIP02-16
Key facts
| Active substance |
Allopregnanolone
|
| Therapeutic area |
Psychiatry
|
| Decision number |
P/0357/2017
|
| PIP number |
EMEA-002051-PIP02-16
|
| Pharmaceutical form(s) |
Intravenous use
|
| Condition(s) / indication(s) |
Treatment of postpartum depression
|
| Route(s) of administration |
Solution for infusion
|
| Contact for public enquiries |
Sage Therapeutics Inc
Tel. +1 6172998380
E-mail: contact@sagerx.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|